Recent Updates
Recently added Catalysts

VK2735

Phase 3

Weight Loss | Small molecule | Other |Viking Therapeutics, Inc.|Last Updated: Apr 7, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials5
Total Enrollment6,148
FDA Designations
No designations recorded
Clinical Trials (5)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)PHASE3 ACTIVE NOT_RECRUITING 1,100 — — Jun 23, 2025Aug 1, 2027Apr 7, 2026127 United States, Puerto Rico
NCT07104500VK2735 for Weight Management Phase 3PHASE3 ACTIVE NOT_RECRUITING 4,500 — — Jun 23, 2025Aug 1, 2027Nov 24, 2025137 United States, Puerto Rico
NCT06828055VK2735 for Weight Management Phase 2 (Venture Oral Dosing)PHASE2 COMPLETED 280 — — Dec 18, 2024Aug 15, 2025Oct 6, 202515 United States
NCT06068946VK2735 for Weight Management Phase 2PHASE2 COMPLETED 176 — — Aug 31, 2023Apr 2, 2024Feb 12, 202520 United States
NCT05203237Phase 1 Study to Evaluate the Safety and Tolerability of VK2735PHASE1 COMPLETED 92 — — Dec 14, 2021Dec 3, 2024Feb 17, 20251 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent change in body weight from baseline to Week 78 in body weight
78 Weeks
Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment
78 Weeks
Percent (relative) change from baseline in body weight after 13 weeks of treatment
13 Weeks

To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

Percent (relative) change from baseline to Week 13 in body weight
13 weeks

To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)
8 days

To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants

Secondary Endpoints
Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment
78 Weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment
13 Weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
13 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Placebo AssignmentPLACEBO_COMPARATORVK2735 Placebo Comparator Once Weekly
Active Assignment (Dose #1)EXPERIMENTALVK2735 7.5mg Once Weekly
Active Assignment (Dose #2)EXPERIMENTALVK2735 12.5mg Once Weekly
Active Assignment (Dose #3)EXPERIMENTALVK2735 17.5mg Once Weekly
Active Assignment (Dose 1)EXPERIMENTALVK2735 7.5mg Once Weekly
Active Assignment (Dose 2)EXPERIMENTALVK2735 12.5mg Once Weekly
Active Assignment (Dose 3)EXPERIMENTALVK2735 17.5mg Once Weekly
Active Assignment (Dose #4)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #5)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #6)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735 (Placebo)PLACEBO_COMPARATORPlacebo
VK2735 (Dose #1)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #2)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #3)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #4)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
Placebo (Part A)PLACEBO_COMPARATORPlacebo administered SC once in healthy participants
VK2735 (Part A)EXPERIMENTALEscalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
Placebo (Part B)PLACEBO_COMPARATORPlacebo administered SC once weekly for four weeks in healthy participants
VK2735 (Part B)EXPERIMENTALEscalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
VK2735 (Part C )PLACEBO_COMPARATORPlacebo administered orally daily for 28 days in healthy participants
VK2735 (Part C)EXPERIMENTALEscalating doses of VK2735 administered daily (PO) in healthy participants.
Interventions
NameTypeDescription
VK2735DRUGVK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
PlaceboDRUGMatching Placebo to VK2735
VK2735 PlaceboDRUGAdministered orally
VK2735 DrugDRUGAdministered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites127

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screenin...

Countries:United StatesPuerto RicoAustralia
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07104383Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 26, 2026NCT07104500primaryCompletionDate: changed
LOWMay 24, 2026NCT07104383studyFirstPostDate: changed
LOWMay 24, 2026NCT07104500studyFirstPostDate: changed